Immunoregulatory Therapy for 2019-nCoV
NCT04268537
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
120
Enrollment
OTHER
Sponsor class
Conditions
2019 nCoV, PD-1
Interventions
DRUG:
PD-1 blocking antibody+standard treatment
DRUG:
Thymosin+standard treatment
OTHER:
standard treatment
Sponsor
Southeast University, China